154 related articles for article (PubMed ID: 14970873)
1. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Schmidt R; Baumann F; Knüpfer H; Brauckhoff M; Horn LC; Schönfelder M; Köhler U; Preiss R
Br J Cancer; 2004 Feb; 90(4):911-6. PubMed ID: 14970873
[TBL] [Abstract][Full Text] [Related]
2. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
Huang Z; Roy P; Waxman DJ
Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
[TBL] [Abstract][Full Text] [Related]
3. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
4. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.
Granvil CP; Madan A; Sharkawi M; Parkinson A; Wainer IW
Drug Metab Dispos; 1999 Apr; 27(4):533-41. PubMed ID: 10101149
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
Roy P; Tretyakov O; Wright J; Waxman DJ
Drug Metab Dispos; 1999 Nov; 27(11):1309-18. PubMed ID: 10534317
[TBL] [Abstract][Full Text] [Related]
7. Gender difference in ifosfamide metabolism by human liver microsomes.
Schmidt R; Baumann F; Hanschmann H; Geissler F; Preiss R
Eur J Drug Metab Pharmacokinet; 2001; 26(3):193-200. PubMed ID: 11695720
[TBL] [Abstract][Full Text] [Related]
8. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.
Lu H; Wang JJ; Chan KK; Philip PA
Xenobiotica; 2006 May; 36(5):367-85. PubMed ID: 16854777
[TBL] [Abstract][Full Text] [Related]
9. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
11. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
12. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
14. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.
Walker D; Flinois JP; Monkman SC; Beloc C; Boddy AV; Cholerton S; Daly AK; Lind MJ; Pearson AD; Beaune PH
Biochem Pharmacol; 1994 Mar; 47(7):1157-63. PubMed ID: 8161344
[TBL] [Abstract][Full Text] [Related]
15. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Di Marco MP; Wainer IW; Granvil CL; Batist G; Ducharme MP
Pharm Res; 2000 Jun; 17(6):645-52. PubMed ID: 10955835
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.
Aleksa K; Matsell D; Krausz K; Gelboin H; Ito S; Koren G
Pediatr Nephrol; 2005 Jul; 20(7):872-85. PubMed ID: 15875221
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
20. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide.
Preiss R; Schmidt R; Baumann F; Hanschmann H; Hauss J; Geissler F; Pahlig H; Ratzewiss B
J Cancer Res Clin Oncol; 2002 Jul; 128(7):385-92. PubMed ID: 12136253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
